Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2

Irure‐Ventura, Juan; Vega, Lara Belmar; Fernández‐Fresnedo, Gema; González-López, Elena; Castro-Hernández, Carolina; Rodrigo-Calabia, Emilio; Heras-Vicario, Milagros; Millán, Juan Carlos Ruíz San; López‐Hoyos, Marcos

doi:10.1016/j.isci.2022.104847

Cited by 9 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the vascular effects of COVID-19 vaccination have yet to be known. Irure-Ventura et al [ 31 ] found that the incidence of new ANCA-positive patients had increased in 2021 compared to 2019 (2.4% vs. 1.2%).…”

Section: Discussionmentioning

confidence: 99%

ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review

et al. 2023

View full text Add to dashboard Cite

Vaccines against SARS-CoV-2 (COVID-19) proved beneficial for COVID-19 disease attenuation and preventing virus spreading. Cumulative reports of the rarity of antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis (AAV) raise concerns about its relationship with COVID-19 vaccination. Several case reports described ANCA-associated pauci-immune glomerulonephritis (ANCA-GN) following COVID-19 vaccination with some uniqueness. We systematically reviewed COVID-19 vaccine-induced ANCA-GN from PubMed, SCOPUS, and Cochrane library databases until 1 January 2023 according to PRISMA guidelines and presented our three cases. Twenty-six cases from 25 articles, including our 3 cases, were analyzed. Most cases were diagnosed following the second dose of the COVID-19 vaccine (59%) with a median (IQR) interval onset of 14 (16) days. The highest prevalence was related to the mRNA-type vaccine. Anti-myeloperoxidase (MPO) ANCA was far more common than the other ANCAs, with various positive autoantibodies. Fourteen cases (out of 29 cases, 48%) had extra-kidney AAV manifestation. Although severe kidney injury was observed in 10/29 (34%), remission was achieved in 89% (25/28) with no death. The mechanisms of the vaccine-inducing ANCA-GN were postulated here. Since ANCA-GN after the COVID-19 vaccine was rare, the benefit of the COVID-19 vaccine could outweigh the risk of ANCA-GN side effects in the pandemic era.

show abstract

Section: Discussionmentioning

confidence: 99%

ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Recently, Irure-Ventura et al reported that 2 out of 35 patients who developed ANCA after SARS-CoV-2 vaccination developed ANCA and AAV after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine. One of the two cases developed ANCA six days after the first dose ( 9 ). A secondary effect from the polyclonal activation induced by the vaccine may be attributable to the production of ANCA by potential autoreactive clones specific for MPO.…”

Section: Discussionmentioning

confidence: 99%

Anti-glomerular Basement Membrane Disease Concomitant with MPO-ANCA Positivity Concurrent with High Serum Levels of Interleukin-26 Following Coronavirus Disease 2019 Vaccination

et al. 2023

View full text Add to dashboard Cite

As coronavirus disease 2019 (COVID-19) vaccine booster campaigns progress worldwide, new reports of complications following COVID-19 vaccination have emerged. We herein report a case of new-onset antiglomerular basement membrane (GBM) disease concomitant with myeloperoxidase-antineutrophil cytoplasmic antibody positivity concurrent with high levels of interleukin (IL)-26 following the second dose of the Pfizer-BioNTech COVID-19 vaccine. The temporal association with vaccination in this case suggests that an enhanced neutrophilic immune response through IL-26 may have triggered necrotizing glomerulonephritis and a T-cell-mediated immune response to GBMs, leading to the development of anti-GBM antibodies, with an enhanced B-cell response after the vaccination triggering anti-GBM IgG and the onset of anti-GBM disease.

show abstract

“…(8)(9)(10)(11)(12)(13)(14)(15)(16)(17) In line with these case reports, studies have reported patients with new-onset or flare-up ulcerative colitis (UC) after COVID-19 mRNA vaccination. (18,19) Whether such occurrence of autoimmunity is coincidental or caused by vaccination against SARS-CoV-2 is unclear; however, Irure-Ventura et al (20) reported an increase in the development of antineutrophil cytoplasmic Abs-associated vasculitis in 2021 (after COVID-19 vaccination) in comparison with that in 2019. Thus, we speculate that administering COVID-19 mRNA vaccines may trigger the development of immune disorders, including UC.…”

mentioning

confidence: 99%

Cytokine and chemokine profiles in ulcerative colitis relapse after coronavirus disease 2019 vaccination

Masuta,

Minaga,

Otsuka

et al. 2024

J. Clin. Biochem. Nutr.

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) vaccines are highly effective; however, vaccine-related adverse events, including autoimmunity, have been reported. Case reports describing relapse or new-onset of ulcerative colitis (UC) after COVID-19 mRNA vaccination are available. However, the molecular mechanisms underlying the development of colonic inflammation associated with COVID-19 mRNA vaccination are poorly understood. Furthermore, it is unclear whether the relapse of UC after COVID-19 vaccination is driven by unique cytokine responses that differ from those of UC not associated with vaccination. mRNAs derived from COVID-19 vaccines are potent inducers of type I IFN response. We encountered three cases of UC relapse after COVID-19 vaccination. mRNA expressions of IFN-α, IFN-β, IL-1β, and IL-12/23p40 showed higher tendency in the colonic mucosa of patients with UC associated with vaccination compared with those not associated with vaccination. In contrast, the expressions of C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10 were comparable. Immunofluorescence analyses also showed higher expression of IFN-α in the colonic mucosa of patients with UC associated with COVID-19 vaccination than in those not associated with vaccination. Taken together, these data suggest that the colonic mucosa of patients with UC who relapsed after COVID-19 vaccination was characterized by enhanced type I IFN responses.

show abstract

Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2

Cited by 9 publications

References 25 publications

ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review

ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review

Anti-glomerular Basement Membrane Disease Concomitant with MPO-ANCA Positivity Concurrent with High Serum Levels of Interleukin-26 Following Coronavirus Disease 2019 Vaccination

Cytokine and chemokine profiles in ulcerative colitis relapse after coronavirus disease 2019 vaccination

Contact Info

Product

Resources

About